InxMed

About

InxMed is a clinical-stage biotech company dedicated to developing innovative, individualized medicines with international impact.

Shanghai,Shanghai,China
1 - 10

Highlights

Details

Last Funding Type: Series B
Last Funding Money Raised: $50M
Industries: Biotechnology,Life Science
Founded date: Jan 1, 2018
Number Of Employee: 1 - 10
Operating Status: Active
Legal Name: InxMed (Shanghai) Co., Ltd.

InxMed is a clinical-stage biotech company focusing on developing "Best-in-Disease Combination" medicines to bring novel treatment options for patients. Our innovations are inspired by patients and driven by an in-depth understanding of disease biology and pharmacology. InxMed is committed to building a translational platform equipped with global-level top-notch know-how and efficient execution capabilities.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

4

$75M ¥130M

InxMed has raised a total of $75M ¥130M in funding over 2 rounds. Their latest funding was raised on Jul 21, 2022 from a Debt Financing round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Jul 21, 2022	Debt Financing	$10M	1	SPD Silicon Valley Bank (SSVB)	—	Detail
May 8, 2022	Series B	$15M	1	Hyfinity Investments	—	Detail
Mar 3, 2022	Series B	$50M	4	CS Capital	—	Detail
Sep 4, 2020	Series A	¥130M	4	Ennovation Ventures China Growth Capital \| CGC	—	Detail

Investors

Number of Lead Investors

Number of Investors

5

9

InxMed is funded by 9 investors. SPD Silicon Valley Bank (SSVB) and Hyfinity Investments are the most recent investors.

Investor Name	Lead Investor	Funding Round
SPD Silicon Valley Bank (SSVB)	Yes	Debt Financing
Hyfinity Investments	Yes	Series B
CS Capital	Yes	Series B
China Growth Capital \| CGC	Yes	Series A
Ennovation Ventures	—	Series B
AIHC Capital	—	Series B
HosenCare Brothers	—	Series B
Grand Yangtze Capital	—	Series A
InnoMed Capital	—	Series A